Chapter 13.Fluvoxamine
Sections
Excerpt
Fluvoxamine is a member of the selective serotonin reuptake inhibitor (SSRI) family of drugs. Initially manufactured by Duphar Laboratories in the United Kingdom in 1971, fluvoxamine was registered as an antidepressant in Switzerland in 1983, becoming the first drug in the now hugely popular SSRI class to reach the market. Since its introduction, fluvoxamine has undergone a wide range of trials to assess its therapeutic potential in depression, several anxiety disorders, and obsessive-compulsive disorder (OCD). Fluvoxamine has been available in the United States since 1994, when it received U.S. Food and Drug Administration (FDA) approval for the treatment of OCD (Ware 1997). More than 28 million people worldwide have been treated with fluvoxamine (Buchberger and Wagner 2002).
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).